BMJ UK BMJ Americas BMJ Brazil BMJ China BMJ India

New drug combo “promising candidate” for on-demand contraceptive pill

  • BMJ
  • /
  • Newsroom
  • /
  • Newsroom
  • /
  • New drug combo “promising candidate” for on-demand contraceptive pill

New drug combo “promising candidate” for on-demand contraceptive pill

Disrupts ovulation when pregnancy risk greatest, but further research warranted

A new combination of drugs has emerged as a “promising candidate” for an on-demand contraceptive pill, suggests preliminary research published online in the journal BMJ Sexual & Reproductive Health.

The combination of ulipristal acetate, currently used as emergency contraception medication, plus the COX-2 inhibitor meloxicam, a type of non-steroidal anti-inflammatory drug, seems to be highly effective at disrupting ovulation at the point in the cycle when the risk of pregnancy is greatest, known as peak fertility.

The days just before ovulation, known as the luteal surge, are when it’s hardest to disrupt ovulation and when fertilisation of the egg is most likely to occur.

Ulipristal acetate disrupts ovulation, but only if taken before the luteal surge begins. Drugs like COX-2 inhibitors, on the other hand, may still be able to disrupt ovulation even after the luteal surge has started.

The researchers therefore wanted to find out if the combination of both drugs might work at peak fertility, with the aim of identifying a lead candidate for a potentially highly effective on-demand contraceptive pill for use before or after sex as needed, or as an emergency contraceptive pill.

Ten healthy women between the ages of 18 and 35 were included in the study, all of whom had regular periods.

Each woman  was monitored through two menstrual cycles: a baseline cycle, to identify normal ovulatory patterns and a treatment cycle, when participants were given a combined dose of ulipristal acetate 30 mg and meloxicam 30 mg around the time of the luteal surge.

Ultrasound scans and key hormones were measured to identify the luteal surge and whether ovulation had occurred or been disrupted. Nine women completed both baseline and treatment cycles and were included in the final analysis.

Ovulation was disrupted in 6 women in the treatment cycle. Most (89%, 8) met some criteria for incomplete ovulation. Treatment cycles were around 3 days longer: this cycle length disruption is especially important for those who may also be using fertility awareness methods, explain the researchers.

This is exploratory research, involving just 9 women, so further studies on safety and effectiveness in larger numbers of women are needed, they emphasise.

But the results are promising, they suggest, because they show the combination of ulipristal acetate plus meloxicam can disrupt ovulation when conception risk is highest, making it “a promising candidate for evaluation as a pericoital oral contraceptive.”  

They add: “When we compare ovulation disruption rates in our study with the previous studies on which our protocol is based, the combination of [ulipristal acetate] and meloxicam disrupted ovulation at each phase of the fertile window more than any other medication previously studied.” 

The findings also suggest that adding meloxicam to ulipristal acetate may boost the latter’s effectiveness as emergency contraception, they say.

Notes for editors
The authors have previously posted a non-peer reviewed, unedited version of this study for feedback from the research community, on a recognised preprint server.

Some of the findings were presented at the Annual Fellowship in Family Planning Meeting in Boston, Massachusetts, May 2019 and at the American Society for Reproductive Medicine Annual Meeting in Philadelphia, October 2019.

Research: Potential candidate for oral pericoital contraception: evaluating ulipristal acetate plus cyclooxygenase-2 inhibitor for ovulation disruption doi 10.1136/bmjsrh-2021-201446
Journal: BMJ Sexual & Reproductive Health

Funding: Society for Family Planning Research Fund 

AMS press release labelling system:

Externally peer reviewed? Yes
Evidence type: Observational
Subjects: People

BMJ Expert Media Panel

If you are a journalist needing to speak to an expert, please click here.

Browse our Expert Media Panel


Latest coverage of BMJ in the national and international media



If you are a journalist who would like to receive our press releases, please provide your details.



Email the UK media relations team for more information.